• SyncroPatch 384

    Next level versatility and flexibility
  • SyncroPatch 384

    True HTS and GigaOhm seals
  • SyncroPatch 384

    Your multi purpose instrument
  • SyncroPatch 384

    Powerful analysis software
  • SyncroPatch 384

    Assay flexibility via high tech
  • SyncroPatch 384

    Heating and cooling of solutions, cells and patch clamp sites

SyncroPatch 384 - For all your patch clamp needs


新型 SyncroPatch 384 是一种革命性的全自动膜片钳系统,由集成有最先进的液体处理系统 Biomek i5 的膜片钳模块组成。 使用 384 通道放大器和一个 384通道移液头,所有384 个细胞都被并行记录,从而产生每天 20,000 个数据点的通量。得益于其易用性和开放式设计,SyncroPatch 384 支持完全自动化并集成到 HTS 环境中。

但 SyncroPatch 384 不仅仅是一个高通量筛选系统,而且可以在您的所有电生理学项目中实施,无论您的通量需求如何。 32 孔操作模式非常适合较小的筛选项目和学术研究,并充分利用了经济实惠的NPC-384芯片。 以 32 的倍数选择您需要并行记录的孔数,您可以在几天内使用剩余的孔。 或者,您可以使用 SyncroPatch 384 进行长达8 小时的无人值守模式的全自动实验。

卓越的数据质量和灵活性使 SyncroPatch 384 成为全球制药公司、CRO 和学术机构等首选的384通道全自动膜片钳系统。


主要特征

  • • 千兆级封接记录
    • 384孔平行记录
    • 32孔模式适用于较少的化合物筛选和研究项目
    • 通常成功率达到>85%
    • 用于快速脱敏配体门控离子通道的快速外液更换(高达110 µl/s)
    • 记录时的內液灌流——通过內液激活通道,例如钙激活K+通道。
    • 高级温度控制可以使实验过程中降低或升高的温度(范围10-37°C)标准化
    • 具有电流钳功能的基本特点
    • 单孔芯片用于高表达细胞系,多孔芯片用于低表达细胞系。 所有芯片都是通过室内质控生产
    • 可以收集样品数据进行量效曲线分析
    • 受益于卓越的服务和技术支持

更多功能请点击下方

 

Hardware and Software

  • Nanion's patch clamp chips are made of borosilicate glass, just like manual patch clamp pipettes, resulting in low capacitance, low compound adsorption plus excellent patch/seal properties.
  • On-deck compound plate preparation – no need for a separate pipetting robot for compound preparation or to prepare compound plates manually.
  • Advantageous volume to surface ratio in measurement chamber preventing loss of sticky compounds to non-specific binding and proper mixing for accurate in-well compound concentration
  • Unlimited compound applications - allows you to setup experiment without any volumetric restraints
  • Independent movement of gripper and pipetting head so that, e.g. compound lids can be removed without the need for pipette tips to be unloaded
  • Small compound volumes for expensive and hard-to-come-by toxins and antibodies
  • Powerful analysis software (flexible batch analysis, IC50 calculation, IV analysis, compatible with Genedata Screener)
  • z-prime calculation and heat maps gives you a fast and visual overview of your data
  • Setting up, editing and analyzing the easy way
  • Different modes of operation – standard and advanced – for simplicity whilst maintaining flexibility for experimental parameters
  • Choose your throughput – with the 32-well mode you can always choose the right throughput for your experiment

Applications:

  • Voltage- and ligand-gated ion channels can be recorded with equally good success rates
  • Cell consumption is small – compatible with stem cell and primary cell use
  • Validated on a wide range of ion channels in recombinant cell lines
  • The SyncroPatch 384 instruments have taken part in the CiPA validation study
  • Suitable for ALL phases in drug discovery
  • Data can be exported in a variety of formats for easy analysis with external tools
  • Flexible enough for the wide range of CRO assays

For detailed information:

Features and Specifications

 

Technical Specifications of the SyncroPatch 384

SyncroPatch 384 Technical Specifications

SyncroPatch 384: Standard Delivery Package

The SyncroPatch 384 includes:

  • Biomek i5 with a 384-pipettor arm, gripper and temperature-controlled deck positions
  • Temperature-controlled patch clamp module
  • Amplifier (384 channels) incl. current clamp
  • Windows 10 OS with PatchControl 384 and DataControl 384 software suite
  • Guided Labware Setup and Method Launcher
  • Temperature-controlled cell hotel
  • Barcode scanner
  • NPC-384 borosilicate recording chips
  • Optional service plans for unmatched

 


Software

 

PatchControl 384

PatchControl 394

PatchControl 384 is a powerful graphical user interface for intuitive, quick and easy setup of voltage protocols and experimental parameters. The recording wells are visualized and color-coded based on user-defined quality criteria, e.g. seal resistance, series resistance or capacitance. With one mouse click, the view switches to online analysis results, for example I/V curves or concentration-response curves.


DataControl 384: The Analysis Software

DataControl 384 is used to visualize and analyze the PatchControl 384-data, employing user-defined data analysis templates. Results (automated IC50, EC50, IV relationship plot generation), compound information, and quality control parameters are exported together in a user-defined export format, automatically generating pdf-reports, and preparing the data for further database integration. This process is straightforward, intuitive and quickly accomplished.


icon sp96   SyncroPatch presentation on the heatmap feature in DataControl  logo pdf   (7.1 MB) 

Consumables

 

NPC-384

NPC 384

The NPC-384 chip is the cost-efficient and high quality consumable for the SyncroPatch 384. It is produced and quality-assured in-house at Nanion headquarters in Munich. Different types of NPC-384 chips are available which should be chosen depending on cell size and application.


Material

The borosilicate glass slide with the patch aperture is encased in a 384 well plate forming wells where the cells and external solutions are delivered. The design of the chip allows perfusion of the internal solution during an experiment.


Features

Each NPC-384 chip contains 384 recording chambers. These sites can be used all at one time or in 32-well mode, parts of the chip can be used in multiples of 32, and the remaining parts used over several days, without a reduction success rate. One chip can be measured on the SyncroPatch 384 and 25 chips can be stacked in the robot for unattended experiments. The open design of the chip makes sample collection and subsequent verification of compound concentration. Additionally, the number of exchanges of either the internal or the external solution is unlimited. NPC-384 chips can be purchased as single hole per well for GOhm seals, or multi-hole per well to increase measured current amplitude and improve success rate.<hr/ >

Available chip types
  • "NPC-384, 1x medium resistance": One hole per well (Order # 221102)
  • "NPC-384, 1x medium resistance plus": One hole per well (Order # 221104)
  • "NPC-384, 4x medium resistance": 4 holes per well (Order # 221402)
  • "NPC-384, 1x high resistance": One hole per well (Order # 221101)
  • "NPC-384, 4x high resistance": 4 holes per well (Order # 221401)
  • "NPC-384, 1x low resistance": One hole per well (Order # 221103)
  • "NPC-384, 4x low resistance": 4 holes per well (Order # 221403)
  • "NPC-384, 8x": 8 holes per well (Order # 221801)
  • Buffer Solutions

    Buffers and Solutions for the SyncroPatch 384/384i/768i

    Reliable buffer solutions are critical for any electrophysiological application. Our goal, therefore, is to provide high-class recording solutions that leave you in no doubt about quality and stability. Our quality assurance includes chemical tests as well as tests on our patch clamp systems of each lot. Our buffers are shipped with the corresponding "Certificates of Analysis" and "Material Safety Data Sheets" (MSDS).


    Available buffers and solutions
    • "External Standard", 500 mL: (Order # 08 3001)
    • "External Standard Ca 10", 500 mL: (Order # 08 3012)
    • "External NMDG 60", 500 mL: (Order # 08 3004)
    • "External NMDG 60 Ca 10", 500 mL: (Order # 08 3011)
    • "External [-] Ca2+ [-] Mg2+", 500 mL: (Order # 08 3003)
    • "Internal CsF 110", 500 mL: (Order # 08 3008)
    • "Internal KF 110", 500 mL: (Order # 08 3007)
    • "Washing solution", 5 L: (Order # 08 3010)

    Data and Applications

    32- well mode for smaller screens or academic investigations

    icon sp96   PE384 32 well modeSyncroPatch 384 data and applications:
    Cells were kindly provided by SB Drug Discovery

    An exemplary 32-well Mode Experiment. A small fraction of the chip can be used at a time, which is ideal for smaller compound screens.
    Consecutive experiments of 32-wells on the same NPC-384 patch clamp chip over multiple days. Success rate and accurate pharmacology remains stable over 8 days as shown in the figure. Nav1.5 recordings in the presence of increasing Mexiletine concentrations.

     

    AMPA Receptor (GluA2) - Activation by Glutamate

    icon sp96   GluR2 PE DataSyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by SB Drug Discovery.

    The AMPA receptor (GluA2) was activated using different concentrations of glutamate (1 µM - 100 µM). Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.
    The lower two images are displaying screenshots of single cell currents after repetitive glutamate applications:
    Left: The same concentration of Glutamate was applied three times.
    Right: Four different Glutamate concentrations were applied in a cumulative manner.

    AMPA Receptor (GluA2) - Cumulative Concentration Response

    icon sp96   GluA2 GluCRC SP384PE SBSyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by SB Drug Discovery.

    The AMPA receptor (GluA2)was activated by increasing concentrations of glutamate on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). L-glutamate was applied for approximately 500 ms in increasing concentrations (A) and a cumulative concentration response curve for glutamate was constructed for 222 wells (C).
    The online analysis values peak amplitude and area under the curve (AUC) are shown versus time in Panel B. The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).

    AMPA Receptor (GluA2) - Pharmacology

    icon sp96   GluR2 PE Data PharmacologySyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by SB Drug Discovery.

    The AMPA receptor (GluA2) was analyzed using different positive and negative allosteric modulators (CNQX, LY404187, LY395153, CP465022, Cyclothiazide). After activating the receptor by application of Glutamate, the modulating compound plus glutamate was applied afterwards. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.
    The lower images on the left hand side are displaying a screenshot of a current after application of the positive modulator LY404187. The EC50 was determined as 379 nM.

    Cardiac Ion Channels - Pharmacology of Sotalol

    CiPA PE CE Pharmacology SotalolIcon CE    CardioExcyte 96 and   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River and Cellular Dynamics.

    The image on the left hand side displays the results of the blocking effect of Sotalol on hERG. The result is in good agreement with manual patch clamp data (Crumb et al., 2016). The compound induced arrhythmia when iPSC-CM were exposed to a minimum concentration of 10 µM. Arrhytmic events were both detected in field potential recordings as well as in the impedance based contractility measurements.

    CaV1.2 - Current Voltage Relationship

    CaV12 CHO CR SP384 IV

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells kindly provided by Charles River.

    CaV1.2 expressed in CHO cells recorded on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). A The screenshot shows the data acquisition and analysis software used on the SyncroPatch 384PE. The online analysis values are shown for a current-voltage experiment. B The raw traces from an example cell elicited by depolarizing steps from -60 mV to 40 mV in 10 mV increments from a holding potential of -80 mV are shown. C The normalized current-voltage plot for an average of 272 cells. A Boltzmann equation fit revealed a V0.5 of activation of -4.8 mV.

     

    CaV1.2 - Pharmacology of Nifedipine, using the CiPA protocol

    icon sp96   CiPA PE CaV1 2 2SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hCaV1.2/β2/α2δ1 current traces in response to the CiPA voltage step protocol and the corresponing current-voltage relationship plot. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 94%. The IC50 value of Nifedipine was determined as 106 nM.

     

    CaV1.2 - Stable recording from frozen stock cells

    icon sp96   170922 CaV1.2 Data SyncroPatch384PESyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hCaV1.2β2/α2δ1 current traces in response to a voltage step protocol and the corresponding current-voltage relationship plot. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 100 %. The cells were used from a frozen cell stock (after induction) and recorded stably for more than 20 minutes. The IC50 value of Nifedipine was determined as 21 nM.

    ClC-1 - Current-voltage plot

    ClC 1 figure current voltage plot SP384 charles rivericon sp96   SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Activation of hClC-1 tail currents expressed in CHO cells recorded on the SyncroPatch 384i (a predecessor model of SyncroPatch 384). A pre-pulse voltage step to +60 mV was followed by voltage steps from -120 mV to +80 mV for 300 ms (increasing in 20 mV steps) and the tail current was measured at the subsequent step to -100 mV. Out of a possible 384 wells, all 384 wells were used for the IV analysis

     

    ClC-1 – Inhibition by 9-AC

    ClC 1 figure Inhibition by 9 ACicon sp96   SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Tail currents of ClC-1 expressed in CHO cells were inhibited by increasing concentration of 9-AC. A single concentration of 9-AC was added to each well and the concentration response curve constructed over multiple wells. The IC50 was calculated to be 6.3 µM for an average of 352 wells. The average current traces are also shown.

     

    GABAA Receptor (α1β2γ2) - Success Rates

    Seal Stat GABAa1

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Bsys.

    Statistic of hGABAA α1β2γ2 cells recorded on one NPC-384 1-hole (1x) patch clamp chip. 57 % of the cells on one NPC-384 chip had seal resistance > 1 GOhm at the beginning and 48% at the end of the experiment. Access (RSeries) was good with 80% of cells with RSeries <20 MOhm at the start of the experiment.

     

     

    GluA2 activation at 110µl/s – speed is key

    icon sp96   PE384 GluA2SyncroPatch 384 data and applications:
    Cells were kindly provided by SB Drug Discovery

    The AMPA receptor (GluA2) was activated using increasing concentrations of glutamate. Measured on the SyncroPatch 384 the whole cell patch methodology and multi-hole chips were used. The faster you apply the ligand, the shorter is the Time to Peak, this means pipetting speed is relevant for accurate pharmacology. The IC50 of Glutamate at 110 µl/s was 460 µM.

     

    Glycine Receptor (GlyRa1) - Reproducible Current Recordings

    Glycine 384 raw OA reproducibleicon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:

    Glycine-mediated current traces and corresponding time plots from 384 simultaneously recorded HEK cells are shown. Multiple additions of 50 µM Glycine produce very robust current responses with similar peaks, providing best conditions for cumulative pharmacology on one cell.

    hERG - Pharmacology at Physiological Temperature using the CiPA Protocol

    CiPA PE hERG Pharmacology 35DegreeCelsiumicon sp96   SyncroPatch 384/768 PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol at 35 degree Celsius. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch clamp methodology (Escin) and multi-hole chips (4 holes per well). The IC50 value of Erythromycin of the peak current was determined as 60.5 µM. 

     

    hERG - Pharmacology using the CiPA Protocol

    CiPA PE hERG Pharmacologyicon sp96   SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using whole cell patch clamp methodology and multi-hole chips (4 holes per well). The IC50 value of the following compounds of the peak current was determined as 4.18 µM for Diltiazem, 37.4 nM for Terfenadine, 971 nM for Quinidine, 63 µM for Mexiletine, 431 nM for Verapamil and 4.54 µM for Ranolazine. 

    hERG - recordings with great stability using the CiPA step ramp protocol

    CiPA PE hERG Pharmacology Stabilityicon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using perforated patch clamp methodology (Escin) and multi-hole chips (4 holes per well). 

    hERG - Stable Recordings with Accurate Pharmacology

    Syncro hERG 2icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications: 
    Cells were kindly provided by Charles River Laboratories.

    Current-voltage relationship of hERG (Kv11.1) expressed in HEK293 is shown along with pharmacology of 4 hERG-active compounds. The current-voltage relationships for all 384 wells (top) using perforated patch (Escin) and multi-hole chips (4 holes per well) are shown. In all 384 wells, a hERG-mediated current was observed with peak amplitude >700 pA at -20 mV. Using a pharmacology voltage protocol, experiments were stable lasting over 20 minutes. Concentration response curves for astemizole, pimozide, cisapride and terfenadine revealed IC50 values consistent with those found in the literature. 

    hERG and Temperature Control

    icon sp96   PE384 hERG TemperatureSyncroPatch 384 data and applications:
    Cells were kindly provided by Charles River Chantest

    Cardiac ion channels are recommended to be recorded at Phys. Temp. (ICH S7B Q&A. 2021). On the SyncroPatch 384, measurement site, cells and solutions can be accurately temperature controlled – in the presence of physiological temperatures the hERG current kinetic is changed to a larger slope and higher amplitude.


     

    KCa1.1 (BK) - High throughput study

    KCa1 1 SampleTracesicon sp96   SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:
    Data kindly provided by Sharan R. Srinivasan1 and Vikram G. Shakkottai1,2
    1Department of Neurology, University of Michigan, Ann Arbor, MI 48109;
    2Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109.

    HEK293 cells stably transfected with BK channels were used to screen over 50,000 compounds, and using clever buffering techniques, targeting only activators of calcium sensitivity for BK channel augmentation. 

    Read more

     

    KCa3.1 (SK4) - Activation by Perfusion of free internal Calcium

    180209 Data PE SK4icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software are showing KCa3.1 raw traces and according time plots (online analysis) to a voltage ramp from -120 mV to + 60 mV over 200 ms. The application of internal Ca2+ is indicated by the yellow bar. The current increased upon application of internal Ca2+ reaching a peak within 1-2 min after the start of the perfusion. Five minutes of stable KCa3.1 current was recorded prior the channel was inhibited by cumulative additions of external Ba2+; first partly (1 mM Ba2+) and then completely (5 mM Ba2+). The recording was performed with perfectly high success rates in whole cell configuration on a multi hole chip (4 holes per well) using the SyncroPatch 384PE (a predecessor model of SyncroPatch 384).

    Kir2.1 - Pharmacology of Barium

    CiPA PE Kir2 1icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing Kir2.1 current traces in response to a voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using the whole cell patch methodology and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  93%. The IC50 value of Barium was determined as 6.38 µM (Literature: 16.2 µM, Schram et al. Cardiovasc Res. 2003).

    KV1.3 - Pharmacology with High Success Rate

    Kv13 384 raw onl norm Quini 2icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Evotec.

    Shown are screenshots of a pharmacology experiment performed with the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). Recordings from 384 KV1.3 expressing CHO cells were performed simultaneously. Original current traces and the peak current over time are displayed. Data are analysed with DataControl384 full analysis tool. With just a few mouse-clicks normalized concentration response curves can be generated. Here, normalized response and the IC50 of Quinidine is shown. Darkening shades of blue indicate increasing compound concentration.

    KV1.5 - Dose response curve of 4-AP

    icon sp96   KV1.5 Data 3845PESyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing a dose-response curve of 4-AP on KV1.5 stably transfected cells. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using multi-hole chips (4 holes per well), the success rate of completed exeriments  was 100%. The IC50 value of 160 µM corresponds well to literature (IC50 4-AP: 270 µM; Gutman et al., Pharmacological Reviews 57: 473-508, 2005). 

    KV4.3 - Pharmacology of Metropolol Tartrate, using the CiPA Protocol

    CiPA PE KV4.3 2icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3 current traces in response to the CiPA voltage step protocol, measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using the whole cell patch methodology and single-hole chips. The IC50 value of Metropolol Tartrate was determined as 128 µM.

     

     

    KV4.3 - Pharmacology of Quinidine

    CiPA PE Kv4 3icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3 current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using the whole cell patch methodology and multi-hole chips (4 holes per well), the success rate of completed experiments was  95.3%. The IC50 value of Quinidine was determined as 21.2 µM (Literature: 79.3 µM, Crumb et al., J Pharmacol Toxicol Methods. 2016).

    KV4.3/KChIP2 - Dose-response curve of Flecanaide

    icon sp96   170922 KV4.3 Data SyncroPatch384PESyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3/KChIP2 current traces in response to a voltage step protocol and the corresponding current-voltage relationship plot. Using whole cell mode in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). The IC50 value of flecainide was determined as 28.3 µM which is in accordance to literature. The success rate for completed experiments was 100%. 

    KV7.1 (KVLQT) - Dose-response curve

    icon sp96   170922 KV7.1 Data SyncroPatch384PESyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV7.1/KCNE (KVLQT/minK) current traces in response to a voltage step protocol and the corresponding current-voltage relationship plot. Using the perforated patch methodology (Escin) in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). The IC50 value of Chromanol 293B was determined as 3.82 µM. The success rate of completed exeriments was 100%. 

    NaV1.5 - Current Voltage Relationship

    NaStrom IV

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by EMD Millipore.

    Borosilicate glass chips are used as the patch clamp substrate, ensuring excellent voltage clamp of the cell membrane and high quality seals. Voltage gated channels such as hNaV1.5 (HEK293) have been used to validate the system. This data example shows the current-voltage characteristics and the corresponding raw current traces of a single cell from a recording on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). The current-voltage plot was fit with a Boltzmann equation revealing a Vhalf of activation of -51 mV for an average of 337 cells.

     

     

    NaV1.5 - Inactivation Protocol

    NaInactivation

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by EMD Millipore.

    Shown are raw current responses of HEK293 cells expressing hNaV1.5 to a double (inactivation) pulse protocol and the corresponding current-voltage plot. The data was fitted with a Boltzmann equation and the Vhalf of inactivation was -84 mV (n = 217).

     

    NaV1.5 - Late Current Analysis using the CiPA Protocol

    CiPA PE NaV1 5 Pharmacology late currenticon sp96   SyncroPatch 384/768 PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing NaV1.5 current traces in response to the CiPA voltage step protocol, measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384) using whole cell patch clamp methodology and single-hole chips. The NaV1.5 late current was activated by the application of 60 nM ATX-II. The IC50 value of Ranolazine of the late sodium current current was determined as 40.4 µM.

     

    NaV1.5 - Lidocaine Dose Response

    NaLidocaine

    icon sp96   SyncroPatch384PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by EMD Millipore

    NaV1.5 expressed in HEK293 cells recorded on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). The concentration response curves for lidocaine block of NaV1.5 were constructed at different holding potential (as indicated) either using a single concentration of compound pera per cell (solid lines) or cumulative concentration response curves (dashed line). The IC50 for lidocaine was shifted by a factor of 35 when holding potential was changed from -120 mV to -80 mV.

    NaV1.7 - Accurate Voltage Clamp

    SyncroPatch 384PE Nav17 CHO Anaxon 384 raw IV 2

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by Anaxon AG.

    CHO cells expressing NaV1.7 were used on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) with a success rate of > 90% for cells which have a seal resistance > 500 MΩ (see inset). A screenshot of the PatchControl 384 software showing current traces in response to a voltage step protocol and the corresponding current-voltage plot.

    NaV1.7 - Frequency Dependent Inhibition

    icon sp96   PE NaV1.7 TetracaineSyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by Anaxon.

    The frequency dependent inhibition of Tetracaine (5 µM, 15 µM and 50 µM) on NaV1.7 currents were investigated. Measured on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384), the whole cell patch methodology and single-hole chips were used. The IC50 value determined from the first pulse of the pulse train was calculated as 41.8 µM, from the second pulse as 9.9 µM and from the 10th pulse as 3.0 µM. 

     

    NaV1.7 - Pharmacology of Lidocaine

    icon sp96   PE NaV1.7 LidocaineSyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by Anaxon.

    The effect of different concentrations of Lidocaine on NaV1.7 currents were investigated. Measured on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) the whole cell patch methodology and single-hole chips were used. The success rate of > 90% for cells which had a seal resistance > 500 MΩ was determined. A value of 0.79 was calculated for the z-factor (characterization of HTS screening assay quality).

    NaV1.8 - I/V Characteristics

    NaV18 IV Syncro384PEicon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications: 
    The CHO cells were kindly provided by Charles River.

    hNaV1.8 recorded on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384). Shown are current responses to increasing voltage steps from -60 to +60 mV (left). Current-voltage plot for an average of 380 cells is shown on the right. Shown are mean of peak amplitudes normalized to the maximum of each cell ± S.E.M. The data was fitted using a Boltzmann equation revealing a Vhalf of activation of -2.7 mV (n = 380), in good agreement with the range found in the literature. 

    NaV1.8 - State Dependent Inhibition

    icon sp96   PE NaV1.8 State dep InhibitionSyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by Charles River.

    State dependent inhibition of tetracaine on NaV1.8 currents was investigated. Measured on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384), the perforated cell patch methodology (Escin) and multi-hole chips were used and compared to single-whole chips. Using a state dependant pulse protocol, the IC50 value determined from the first pulse (C1) was calculated as 54.3 µM (Hill coefficient = 1.50), and from the second pulse (C2) as 1.27 µM (Hill coefficient = 0.62). 

     

    NaV1.9 - Pharmacology

    NaV1.9 Dataset PE 1icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384) data and applications:
    Cells were kindly provided by Icagen.

    Screenshots of the PatchControl 384 software showing hNaV1.9 current traces in response to a voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  86%. NaV1.9 is TTX insensitive. The IC50 value of lidocaine of the peak current was determined as 350 µM (Literature: 356 µM), the IC50 value of tetracaine of the peak current was determined as 12.5 µM (Literature: 32 µM).

    NMDA NR1/NR2A - Activation and Modulation

    NMDA 384well view

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were kindly provided by B'Sys.

    Here, activation and modulation of the NR1/NR2A subunit containing NMDA receptors are shown. Currents were evoked by application of 10 µM Glutamate in the presence of 10 µM Glycine.

    Application of the neurosteroid Pregnenolone sulfate (PS) potentiates the current response induced by Glutamate. The potency of PS was analysed in a single-point screen. The EC50 of PS (39.6 µM), comprising 74% of the cells is nicely corresponding to litereature values (Irwin, et al. Neurosci. Lett. 1992)

    P2X2/ P2X3 - Activation by ATP on the SyncroPatch 384PE

    P2X23 CHOCells ATP SP384icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:
    Cells were engineered and kindly supplied by Axxam

    P2X2/3 recorded from CHO cells on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384). P2X2/3 was activated by increasing concentrations of ATP with an EC50 = 1.1 µM (n = 191). ATP was applied for approximately 1.5 s using the ‘Ligand Puff’ function of the SyncroPatch 384PE. Average traces and concentration response curve shown for 191 cells. Success rate was 99% for completed experiment (191 wells from a possible 192). Multi-hole (4 holes per well) chips were used.

    P2X2/ P2X3 - Block by suramin on the SyncroPatch 384PE

    P2X23 CHO Cells suramin SP384icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications: 
    Cells were engineered and kindly supplied by Axxam

    P2X2/3 recorded from CHO cells on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384). P2X2/3 was activated by 10 µM ATP and blocked by increasing concentrations of suramin with an IC50 = 17.7 ± 0.9 µM (n = 372). Average traces and concentration response curve shown for 372 cells. Success rate was 97% for completed experiment (372 wells from a possible 384). Multi-hole (4 holes per well) chips were used.

    P2X2/ P2X3 - High throughput screening on the SyncroPatch 384PE

    P2X23 CHO Cells Suramin SP384 Screenshoticon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications: 
    Cells were engineered and kindly supplied by Axxam

    Inhibition of P2X2/3 by suramin. Suramin was pre-incubated at each concentration for 3 - 5 mins followed by co-application with 10 µM ATP. All 3 concentrations of suramin were applied to each well and a cumulative concentration response curve was constructed for n = 372 wells out of a possible 384. Success rate was 97% for completed experiments.

    Piezo1 in Neuro2A cells - activation by Yoda1

    Piezo1 Neuro2A Rotordam Database.jpgicon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:

    Piezo1 channels endogenously expressed in Neuro2A cells were investigated on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384). Screenshot of the PatchControl 384 software during an experiment. B Statistical analysis of the currents at -100mV (left) and at 80 mV (right). 140 out of 384 Neuro2A cells (37%) passed the quality criteria and 85 cells (60% of the valid cells) were considered as Yoda1 responders.

    Data from Rotordam et al, 2019.

     

    Piezo1 in red blood cells - activation by Yoda1

    Piezo1 RBC Syncroicon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:

    Current response of Piezo1 activated by Yoda1 in patient cells with the novel PIEZO1 mutation (R2110W) compared to healthy red blood cells (RBCs). Shown are raw data traces (top) and statistical analysis of all measured cells, independent of their response to Yoda1 (bottom).

    Data from Rotordam et al, 2019.

     

    Piezo1 in red blood cells - Hereditary Xerocytosis

    Piezo1 RBC Syncroicon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) data and applications:

    Whole-cell recordings of ion currents from RBCs of healthy donors and Hereditary Xerocytosis patients. Different mutations in the PIEZO1 gene were compared with controls. Aa The P50.2 mutation resulted in current conductance that was unchanged compared with transport controls, but showed increased conductance compared with general controls (Ab). The mutation P52.1 showed decreased conductance compared with transportation controls (Ba) and general controls (Bb).

    Data from Petkova-Kirova et al, 2019.

     

    TRPA1 - Activation by carvacrol

    TRPA1 Carvacrol SP384iicon sp96  SyncroPatch 384i (a predecessor model of the SyncroPatch 384) data and applications: 

    Cells were kindly provided by AcCELLerate.

    Activation of TRPA1 expressed in CHO cell on the SyncroPatch 384i (a predecessor model of the SyncroPatch 384). A Screenshot of the PatchControl 384 software depicts raw data traces of TRPA1- expressing CHO cells as recorded on one NPC-384 patch clamp chip (4 holes). A single concentration of carvacrol was added to each well and the concentration response curve calculated across the plate. B Average CRC (left) for carvacrol for n = 355 wells and average traces (right). TRPA1 was robustly activated by carvacrol. At higher concentrations (above 400 µM) desensitization of the channel was observed (tachyphylaxis) which resulted in smaller amplitudes upon repeated application.

    TRPA1 - Inhibition by A967079 and AMG0902

    TRPA1 Inhibition SP384icon sp96   SyncroPatch 384i (a predecessor model of the SyncroPatch 384) data and applications: 
    Cells were kindly provided by AcCELLerate.

    Inhibition of TRPA1 by A967079 and AMG0902. A TRPA1-mediated responses were blocked by A967079 in a concentration-dependent manner with an IC50 value (12.4 nM) in good agreement with the literature value of 50 nM. B TRPA1-mediated responses were blocked by AMG0902 in a concentration-dependent manner with an IC50 value of 48 nM (n = 349) in good agreement with the literature value of 68 nM.

     

    TRPM8 and Temperature Control

    icon sp96   PE384 TRPM8SyncroPatch 384 data and applications:
    Cells were kindly provided by Charles River Chantest

    At RT, the TRPM8 current was activated using increasing concentrations of Menthol (left). Measurement site, cells and solutions can be accurately temperature controlled – in the presence of temperatures 38°C, 25°C, 18°C and 12 °C the current size of temperature regulated TRPM8 changes accordingly (right). TRPM8 is activated at temperatures < 25°C.

     

    Testimonials & Case Studies

    Dr. David Dalrymple - Statement about the SyncroPatch 384PE

    icon sp96   “As a leading ion channel contract research organization running one of the most comprehensive ranges of ion channel assays, SB Drug Discovery has been impressed with the flexibility and reliability of the SyncroPatch 384PE (a predecessor model of SyncroPatch 384i), enabling development of a range of varied and complex ion channel assay for both high throughput screening and hit-to-lead profiling purposes. The SyncroPatch has proven to be a crucial addition to SB’s ion channel capabilities and in partnership with expert advice from Nanion’s support team has enabled SB to advance its ion channel capabilities to the forefront of ion channel drug discovery research..“

    Dr. David Dalrymple
    Business Development Director at SB Drug Discovery

    Prof. Al George - Statement about the SyncroPatch 384PE

    icon sp96   “We are extraordinarily excited about installing the first SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) in an academic setting in North America. The enormous throughput, intuitive software and robust liquid handling capabilities along with superior seal quality, stability and high success rates convinced us to purchase the instrument. The SyncroPatch 384PE will enable us to perform detailed high throughput analysis of genetic variants in human ion channels at a previously unobtainable scale, and will form the cornerstone of a new HTS facility we are building. We also look forward to upgrading to 768 wells in the near future.“

    Dr. Al George
    Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Prof. Al George - A New Era is Emerging for Ion Channel and Channelopathy Research

    icon sp96  “... the SyncroPatch has revolutionized our ability to determine the functional consequences of hundreds of human ion channel variants, which could be considered one of the most significant recent advances in channelopathy research.”


    Prof. Dr. Al George
    Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Download the full customer case study here:

    icon sp96   SyncroPatch 384i (a successor of SyncroPatch 384PE) Customer Case Study: logo pdf   (3.1 MB)
    Prof. Dr. Al George, Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Prof. Jamie Vandenberg - Statement about SyncroPatch Technology

    icon sp96   “In my lab we use the SyncroPatch 384PE, as it allows us to reliably screen KCNH2 mutations, the gene encoding hERG K+ channels, in high-throughput. This is a very fast process and it enables us to screen large mutation libraries. Recently, we have validated a high-throughput functional phenotyping assay capable of distinguishing benign KCNH2 variants from those that have a dominant negative effect, using the SyncroPatch 384PE. We are very happy with this result and plan to expand assay development to other ion channel genes.”

    Prof. Dr. Jamie Vandenberg, co-deputy director and head of cardiac electrophysiology 
    The Victor Chang Cardiac Research Institute, Australia

    Nina Braun - Statement about the SyncroPatch 384i

    icon sp96   “I measured CRCs for activation and steady-state desensitization, as well as peptide modulation of the channel, and got fantastic support from Søren Friis both with technical questions and assay design .The SyncroPatch and its software are easy to use and allow for versatile assay design. The team at Nanion goes out of their way to help with all questions and requests that come up, and they host fantastic user meetings for idea exchange. After four years using the SyncroPatch, I can highly recommend it.”“

    Nina Braun 
    University of Copenhagen

    Tutorials

    Basic principles of external solution exchange and compound addition



    Also applies to the SyncroPatch 384


     

    Webinars and Movies

    Webinars
    Movies

    14.10.2020 | Webinar: Development and validation of ASIC1a ligand-gated ion channel drug discovery assays on automated patch clamp platforms

    icon sp96  SyncroPatch 384i and icon pl Patchliner Webinar

    Date: October 14. 2020

    201012 Blog Image VUM 2020

    Speakers:

    Dr. Marc Rogers (Metrion Biosciences; U.K.)


    This is an on-demand webinar from Nan]i[on and Friends 2020.

    15.10.2020 | Webinar: Turning Cells into Reagents

     icon pl SyncroPatch 384i Webinar

    Date: October 15. 2020

    201012 Blog Image VUM 2020

    Speakers:

    Dr. Oliver Wehmeier (acCELLerate GmbH) and Dr. Tim Strassmaier (Nanion Technologies)

     


    This is an on-demand webinar from Nan]i[on and Friends 2020.

    15.10.2020 | Webinar: ICH S7B best practices considerations - New Q&As and Benchmarking best practices

     icon pl Patchliner and  icon sp96 SyncroPatch 384i Webinar

    Date: October 15. 2020

    201012 Blog Image VUM 2020

    Speakers:

    Dr. Sonja Stoelzle-Feix (Nanion Technologies)

     


    This is an on-demand webinar from Nan]i[on and Friends 2020.

    15.10.2020 | Webinar: Benchmarking best practices and calibration standards for HTS hERG recordings for improved proarrhythmic assessment

     icon pl Patchliner and  icon sp96 SyncroPatch 384i Webinar

    Date: October 15. 2020

    201012 Blog Image VUM 2020

    Speakers:

    Dr. Alison Obergrussberger (Nanion Technologies)

     


    This is an on-demand webinar from Nan]i[on and Friends 2020.

    16.10.2020 | Webinar: Emerging Role of LRRC8 Volume-Regulated Anion Channels in the Skin

     icon sp96 SyncroPatch 384i Webinar

    Date: October 16. 2020

    201012 Blog Image VUM 2020

    Speakers:

    Dr. Torsten Fauth (BRAIN AG)
    Dr. Oliver Rauh (Technical University of Darmstadt)
    Giustina Rotordam (Nanion Technologies)


    This is an on-demand webinar from Nan]i[on and Friends 2020.

    2020 - What is the Syncropatch 384PE and what are the benefits of the Syncropatch 384PE?

    icon sp96  SyncroPatch 384PE product video

     The Victor Chang Cardiac Research Institute's Innovation Centre is one of the only two centres in Australia that houses the Syncropatch 384PE. The Syncropatch 384PE enables high throughput quantification of electrical signals in cells. In this video, Dr Jeffrey McArthur explains how it works, the advantages of using the Syncropatch384PE to fast track your experiments and how it can benefit your research.

    2019 - SyncroPatch 384i Product Video

    icon sp96  SyncroPatch 384i product video

    200831 blog image SyncroPatch Product Video

    The SyncroPatch 384i – is a giga-ohm seal HTS automated patch clamp platform based on the newly introduced and state-of-the art Biomek i5 liquid handler.

    It provides effortless ion channel screening coupled with unmatched flexibility, ease-of-use and reliability. The SyncroPatch 384i builds on the success of the SyncroPatch 384PE, which has been globally established as the preferred automated patch clamp workhorse in Pharma, Biotech, CRO and academia.

    2018 - HTS Phase I study: an update on progress of the CiPA Ion Channel Work Stream using the SyncroPatch 384PE and Patchliner

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i),   icon pl   Patchliner and   Icon CE   CardioExcyte 96 Oral Presentation

    Presenter: 
    Tim Strassmaier, Nanion Technologies Inc. USA
    Source:
    Webinar: "CiPA study: Bridging ion channel and myocyte data", September 12, 2018

    2018 - Biophysical and Pharmacological Characterization of Voltage-Gated Sodium Channels Involved in Pain Pathways

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) Oral Presentation Video

    Presenter: 
    Dr. Markus Rapedius, Senior Scientist, Nanion Technologies

    Downloads:

    Application Notes

    AMPA receptor (GluA2) - "Activation, potentiation and inhibition of AMPA receptors on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note:   logo pdf   (3.1 MB)
    Cells were kindly provided by SB Drug Discovery.

    ASIC3 - "Activation and Inhibition of human ASIC3 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note:   logo pdf   (2.2 MB)
    Cells were kindly provided by Millipore.  

    Assay Ready TRP-Channel Expressing Cells - a Flexible Tool to Screen for New Drug Candidates

    icon sp96   SyncroPatch 384i (a predecessor model of SyncroPatch 384) application note:   logo pdf   (1.0 MB)
    Patch Ready Cells provided by acCELLerate

    Cardiac Ion Channels - "High Throughput Screening of Cardiac Ion Channels"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384)   icon pl   Patchliner   Icon CE   CardioExcyte 96 application note   logo pdf   (2.3 MB)

    Cardiac Ion Channels - "Simultaneous Assessment of CiPA Stipulated Ion Channels on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (1.3 MB)
    Cells were kindly provided by Charles River.

    Cardiomyocytes - "Combining automated patch clamp, impedance and EFP of hiPSC-CMs"

    Icon CE   CardioExcyte 96   icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384)   icon pl   Patchliner Application Note 
    Cells kindly provided by Takara-Clonetech.

    CaV1.2 - "High Throughput Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (2.7 MB)
    Cells were kindly provided by SB Drug Discovery.  

    CaV1.2 - "Stability and Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (5.3 MB)
    Cells were kidly provided by Charles River.

    CaV1.2 - "Stable Recordings and High Throughput Pharmacology of Assay Ready CaV1.2 Cells on the SyncroPatch 384"

    icon sp96   SyncroPatch 384 application note:   logo pdf   (1.6 MB)
    Cells were kindly provided by NMI TT Pharmaservices, Steinbeis-Innovationszentrum Zellkulturtechnik and acCELLerate

    CaV3.2 - "High Throughput Pharmacology of CaV3.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.  

    CFTR - "Different modes of activation of CFTR recorded on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (5.7 MB)

    hASIC1a - "Pharmacology of human ASIC1a channels on Nanion’s SyncroPatch 384i"

    icon sp96   SyncroPatch 384i (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (1.4 MB)
    Cells were kindly provided by Charles River.

    hClC-1 - "Characterization of hClC-1 on the SyncroPatch 384"

    icon sp96   SyncroPatch 384 application note:   logo pdf   (1.6 MB)
    Cells were kindly provided by Charles River

    HCN2 receptor - "Biophysical modulation of hHCN2 by bPAC recorded on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (1.0 MB)
    Cells were engineered and kindly provided by Axxam S.p.A.

    hERG - "High Throughput Pharmacology of hERG Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (0.6 MB)

    hNaV1.9 - "High Throughput Pharmacology of NaV1.9 Channels on Nanion’s SyncroPatch 384"

    icon sp96   SyncroPatch 384 (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (1.6 MB)
    Cells kindly provided by Icagen, Inc., USA.

    hTRPA1 - "Reproducible activation and pharmacology of hTRPA1 on the SyncroPatch 384"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (3.1 MB)
    Cells were kindly provided by Charles River

    nAChRα4β2 - "Pharmacology of human α4β2 nAChR recorded on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (0.8 MB)
    Cells were engineered and kindly provided by SB Drug Discovery.  

    NaV1.5 - "High Throughput Pharmacology of NaV1.5 Channels on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384i (a predecessor model of the SyncroPatch 384) application note   logo pdf   (1.6 MB)
    Cells were kindly provided by Millipore.

    NaV1.5 - "Increase throughput by recording in unattended mode on the SyncroPatch 384"

    icon sp96   SyncroPatch 384PE and SyncroPatch 384i (a predecessor model of the SyncroPatch 384) application note:   logo pdf   (2.2 MB)
    Cells were kindly provided by Charles River.  

    NaV1.5 - "NaV1.5-ΔKPQ late INa current properties and pharmacology on the SyncroPatch 384i"

    icon sp96   SyncroPatch 384i (a predecessor model of the SyncroPatch 384) application note   logo pdf (1.5 MB)
    Cells were kindly provided by Metrion Biosciences.

    NaV1.7 - "Characterization of hNaV1.7 on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note   logo pdf   (0.7 MB)
    Cells were kindly provided by Anaxon.

    NaV1.8 - "Stability and reproducibility of hNaV1.8 recordings on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note   logo pdf   (1.4 MB)
    Cells were kindly provided by Charles River.

    Neurons - "Electrophysiological recordings of LGIC and AA transporters in iCell® GlutaNeurons"

    icon pl   Patchliner,  icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and   Icon N1   SURFE2R N1 application note:   logo pdf   (0.5 MB)
    Cells were kindly provided by FUJIFILM Cellular Dynamics, Inc.  

    NMDA Receptors (NR1/NR2B) - "Activation and Inhibition of human NMDA Channels on Nanion`s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note   logo pdf   (1.7 MB)
    Cells were kindly provided by Charles River.

    P2X2 / P2X3 - "Pharmacology of P2X2/3 channels recorded on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note:   logo pdf   (5 MB)
    Cells were engineered and kindly provided by Axxam S.p.A., Milan.  

    P2X3 - "Activation and inhibition of P2X3 channels recorded on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note:   logo pdf   (1.5 MB)
    Cells were engineered and kindly provided by Axxam S.p.A., Milan.  

    TASK-1 - "Activation and Inhibition of TASK-1 on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note:   logo pdf   (3.1 MB)
    Cells were kindly provided by SB Drug Discovery.

    TMEM16A (ANO1) - "Internal perfusion of Ca2+ to activate TMEM16A/ANO1 on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note   logo pdf   (1.1 MB)
    Cells were kindly provided by SB Drug Discovery.

    TREK-1 - "Activation and inhibition of TREK-1 on Nanion’s SyncroPatch 384PE"

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (6.0 MB)
    Cells were kindly provided by SB Drug Discovery.

    TRPA1 - "High Throughput Activation and Block of hTRPA1 on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.

    TRPC5 - "Internal perfusion of Ca2+ to activate hTRPC5 on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note   logo pdf   (1.7 MB)
    Cells were kindly provided by Charles River.

    Publications

    2021 - The Schizophrenia Variant V1282F in SCN2A Causes Functional Impairment of NaV1.2

    icon sp96 SyncroPatch Publication in Journal of Schizophrenia Research (2021)

    Authors:
    Kohlnhofer B., Liu Y., Woodruff G., Lovenberg T., Kohlnhofer B., Liu Y., Woodruff G., Bonaventure P., and Harrington AW.

    2021 - Neurogranin, Encoded by the Schizophrenia Risk Gene NRGN, Bidirectionally Modulates Synaptic Plasticity via Calmodulin-Dependent Regulation of the Neuronal Phosphoproteome

    icon sp96SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) publication in Biological Psychiatry (2021)

    Authors:
    Hwang H., Szucs M.J., Ding L.J., Allen A., Ren X., Haensgen H., Gao F., Rhim H., Andrade A., Pan J.Q., Carr S.A., Ahmad R., Xu W.

    2021 - Mechanism of hERG inhibition by gating-modifier toxin, APETx1, deduced by functional characterization

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) publication in BMC Molecular and Cell Biology (2021)

    Authors:
    Matsumura K., Shimomura T., Kubo Y., Oka T., Kobayashi N., Imai S., Yanase N., Akimoto M., Fukuda M., Yokogawa M., Ikeda K., Kurita J., Nishimura Y., Shimada I., Osawa M.

    2021 - High-throughput characterization of photocrosslinker-bearing ion channel variants to map residues critical for function and pharmacology

    icon pl   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) Pre-Publication in bioRxiv (2021)

    Authors:
    Braun N., Friis S., Ihling C., Sinz A., Andersen J., Pless S.A.

    2021 - Heterozygous KCNH2 variant phenotyping using Flp-In HEK293 and high-throughput automated patch clamp electrophysiology

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) pre-print publication in bioRxiv (2021)

    Authors:
    Ng C-A., Farr J., Young P., Windley M.J., Perry M.D., Hill A.P., Vandenberg J.I.

    2021 - From High-Throughput Screening to Target Validation: Benzo[d]isothiazoles as Potent and Selective Agonists of Human Transient Receptor Potential Cation Channel Subfamily M Member 5 Possessing In Vivo Gastrointestinal Prokinetic Activity in Rodents

    icon sp96 SyncroPatch 384 Publication in Journal of Medicinal Chemistry (2021)

    Authors:
    Barilli A., Aldegheri L., Bianchi F., Brault L., Brodbeck D., Castelletti L., Feriani A., Lingard I., Myers R., Nola S., Piccoli L., Pompilio D.,Raveglia L.F., Salvagno C., Tassini S., Virginio C., Sabat M.

    2021 - Fluorescent- and tagged-protoxin II peptides: potent markers of the Nav1.7 channel pain target

    icon sp96SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) Publication in British Journal of Pharmacological (2021)

    Authors:
    Montnach J., De Waard S., Nicolas S., Burel S., Osorio N., Zoukimian C., Mantegazza M., Boukaiba R., Béroud R., Partiseti M., Delmas P., Marionneau C., De Waard M.

    2021 - Dyshomeostatic modulation of Ca2+-activated K+ channels in a human neuronal model of KCNQ2 encephalopathy (2)

    icon sp96  SyncroPatch 768 PE (a predecessor model of the SyncroPatch 384 instrument) publication in Nature (2021)

    Authors:
    Simkin D., Marshall K.A., Vanoye C.G., Desai R.R., Bustos B.I., Piyevsky B.N., Ortega J.A., Forrest M., Robertson G.L., Penzes P., Laux L.C., Lubbe S.J., Millichap J.J., George Jr A.L., Kiskinis E.

    2021 - Disease-linked super-trafficking of a potassium channel

    icon sp96  SyncroPatch 768 PE (a predecessor model of the SyncroPatch 384 instrument) publication in Journal of Biological Chemistry (2021)

    Authors:
    Huang H.,Chamness L.M., Vanoye C.G., Kuenze G., Meiler J., George A.L., Schlebach J.P., Sanders C.R.

    2021 - Differential contributions of M1 and pre-M1 to ion selectivity in ASICs and ENaCs

    icon sp96 SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) prepublication in bioRxiv (2021)

    Authors:
    Sheikh Z.P. , Wulf M., Friis S., Althaus M., Lynagh T., Pless S.A.

    2021 - Comprehensive preclinical evaluation of how cardiac safety profiles of potential COVID-19 drugs are modified by disease associated factors

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) prepublication in Authorea (2021)

    Authors:
    TeBay C., McArthur J., Mangala M., Kerr N., Heitmann S., Perry M., Windley M., Vandenberg J., Hill A.

    2021 - Cation and anion channelrhodopsins: Sequence motifs and taxonomic distribution

    icon sp96  SyncroPatch 384i (a predecessor model of the SyncroPatch 384) Pre-Publication in bioRxiv (2021)

    Authors:
    Govorunova E.G., Sineshchekov O.A., Li H., Wang Y., Brown L.S., Palmateer A., Melkonian M., Cheng S., Carpenter E., Patterson J., Wong G. K-S., Spudich J.L.

    2021 - Applying the CiPA Approach to Evaluate Cardiac Proarrhythmia Risk of some Antimalarials Used Off‐label in the First Wave of COVID‐19

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) prepublication in Clinical and Translational Science (2021)

    Authors:
    Delaunois A., Abernathy M., Anderson W.D., Beattie K.A., Chaudhary K.W., Coulot J., Gryshkova V., Hebeisen S., Holbrook M., Kramer J., Kuryshev Y., Leishman D., Lushbough I., Passini E., Redfern W.S., Rodriguez B., Rossman E.I., Trovato C., Wu C., Valentin J-P.

    2021 - A Massively Parallel Trafficking Assay Accurately Predicts Loss of Channel Function in KCNH2 Variants

    icon sp96 SyncroPatch 384PE (a predecessor to the SyncroPatch 384 model) Publication in BioRxiv (2021)

    Authors:
    Ng C-H.Ullah R.Farr J.Hill A.P, Kozek K.A., Vanags L.R.Mitchell D.Kroncke B.M., Vandenberg J.I.

    2020 -Application of High-Throughput Automated Patch-Clamp Electrophysiology to Study Voltage-Gated Ion Channel Function in Primary Cortical Cultures

     icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in SLAS Discovery (2020)

    Authors:
    Toh M.F., Brooks J.M., Strassmaier T., Haedo R.J., Puryear C.B., Roth B.L., Ouk K., Pin S.S.

    2020 - VU0606170, a Selective Slack Channels Inhibitor, Decreases Calcium Oscillations in Cultured Cortical Neurons

    icon sp96  SyncroPatch 768 PE (a predecessor model of the SyncroPatch 384 instrument) publication in ACS Chemical Neuroscience (2020)

    Authors:
    Spitznagel B.D., Mishra N.M., Qunies A.M., Prael F.J., Du Y., Kozek K.A., Lazarenko R.M., Denton J.S., Emmitte K.A., Weaver C.D.

    2020 - Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk

     icon sp96 SyncroPatch 384 (a predecessor model of the SyncroPatch 768i instrument) publication in Cell Stem Medicine (2020)

    Authors:
    Davies M.R., Martinec M., Walls R., Schwarz R., Mirams G.R., Wang K., Steiner G., Surinach A., Flores C., Lave T., Singer T., Polonchuk L.

    2020 - Trends in the Development of Diagnostic Tools for Red Blood Cell-Related Diseases and Anemias

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i instrument) publication in Frontiers in Physiology (2020)

    Authors:
    Kaestner L., Bianchi P.

    2020 - Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine

     icon sp96   SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in The Journal of Clinical Investigation (2020)

    Authors:
    Shen W., Ren W., Zhai S., Yang B., Vanoye C.G., Mitra A., George AL. Jr., Surmeier D.J.

    2020 - Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment

    icon pl   Patchliner and   icon sp96   SyncroPatch 384i (SyncroPatch 384PEa predecessor model) publication in the Journal of Pharmacological and Toxicological Methods (2020)

    Authors:
    Brinkwirth N., Takasuna K., Masafumi D., Becker N., Obergrussberger A., Friis S., Furukawa Y., Hasegawa Y., Oka T., Ohtsuki A., Fertig N., Stoelzle-Feix S.

    2020 - Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

    icon pl Patchliner and  icon sp96 SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in Cell Stem Cell (2020)

    Authors:
    McKeithan W. L., Feyen D.A.M., Bruyneel A.A.N., Okolotowicz K.J., Ryan D.A., Sampson K.J., Potet F., Savchenko A., Gómez-Galeno J., Vu M., Serrano R., George Jr. A.L., Kass R.S., Cashman J.R., Mercola M.

    2020 - Predicting Functional Effects of Missense Variants in Voltage-Gated Sodium and Calcium

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) Publication in Science Translational Medicine (2020)

    Authors:
    Heyne H.O., Baez-Nieto D., Iqbal S., Palmer D., Brunklaus A., Johannesen K.M., Lauxmann S., Lemke J.R., Møller R.S., Pérez-Palma E., Scholl U., Syrbe S., Lerche H., May P., Lal D., Campbell A.J., Pan J., Wang H.-R., Daly M.J.

    2020 - Novel Expression of GABAA Receptors on Resistance Arteries That Modulate Myogenic Tone

    icon sp96   SyncroPatch 96 (a predecessor model of the SyncroPatch 384i) Publication in Journal of Vascular Research (2020)

    Authors:
    Yim P.D., Gallos G., Lee-Kong S.A., Dan W., Wu A.D., Xu D., Berkowitz D.E., Emala C.W.

    2020 - Mechanism and site of action of big dynorphin on ASIC1a

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) Publication in PNAS (2020)

    Authors:
    Borg C.B., Braun N., Heusser S.A., Bay Y., Weis D., Galleano I., Lund C., Tian W., Haugaard-Kedström L.M., Bennett E.P., Lynagh T., Strømgaard K., Andersen J., Pless S.A.

    2020 - Ion Channels and Relevant Drug Screening Approaches

    icon sp96   SyncroPatch 384i editorial found in SLAS Discovery (2020)

    Authors:
    McGivern, J.G., Ding M.

    2020 - High-throughput reclassification of SCN5A variants

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) Publication in The American Journal of Human Genetics (2020)

    Authors:
    Glazer A.M., Wada Y., Li B., Muhammad A., Kalash O.R., O’Neill M.J., Shields T., Hall L., Short L., Blair M.A., Kroncke B.M., Capra J.A., Roden D.M

    2020 - High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KCNH2: Deep mutational scan of KCNH2 trafficking

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i instrument) Pre-publication in bioRxiv Biology (2020)

    Authors:
    Kozek K.A., Glazer A.M., Ng C.-A., Blackwell D., Egly C.L., Vanags L.R., Blair M., Mitchell D., Matreyek K.A., Fowler D.M., Knollmann B.C., Vandenberg J., Roden D.M., Kroncke B.M.

    2020 - GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes

    icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i) pre-publication in bioRxiv (2020)

    Authors:
    Potet F., Egecioglu D.E., Burridge P.W.,George A.L. Jr.

    2020 - Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

    icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in Medicinal Chemistry (2020)

    Authors:
    Scott J.S., Moss T.A., Balazs A., Barlaam B., Breed J., Carbajo R.J., Chiarparin E., Davey P.R.J., Delpuech O., Fawell S., Fisher D.I., Gagrica S., Gangl E.T., Grebe T., Greenwood R.D., Hande S., Hatoum-Mokdad H., Herlihy K., Hughes S., Hunt T.A., Huynh H., Janbon S.L.M., Johnson T., Kavanagh S., Klinowska T., Lawson M., Lister A.S., Marden S., McGinnity D.F., Morrow C.J., Nissink W.M., O'Donovan D.H., Peng B., Polanski R., Stead D.S., Stokes S., Thakur K., Throner S.R., Tucker M.J., Varnes J., Wang H., Wilson D.M., Wu D., Wu Y., Yang B., Yang W.

    2020 - Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells

    icon pl   Patchliner and   icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i instrument) publication in Nature Scientific Reports (2020)

    Authors:
    Kramer J., Himmel H.M., Lindqvist A., Stoelzle-Feix S., Chaudhary K.W., Li D., Bohme G.A., Bridgland-Taylor M., Hebeisen S., Fan J., Renganathan M., Imredy J., Humphries E.S.A, Brinkwirth N., Strassmaier T., Ohtsuki A., Danker T., Vanoye C., Polonchuk L., Fermini B., Pierson J.B. & Gintant G.

    2020 - Conservation and divergence in NaChBac and NaV1.7 pharmacology reveals novel drug interaction mechanisms

     icon sp96   SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in Nature Scientific Reports Journal (2020)

    Authors:

    Zhu W., Li T., Silva J. R., Chen J.

    2020 - Computer modeling of whole-cell voltage-clamp analyses to delineate guidelines for good practice of manual and automated patch-clamp

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i instrument) pre-publication in BioRxiv (2020)

    Authors:
    Montnach J., Lorenzini M., Lesage A., Simon I., Nicolas S., Moreau E., Marionneau C., Baró I., De Waard M., Loussouar G.

    2020 - Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker

    icon sp96  SyncroPatch 384PE  (a predecessor model of the SyncroPatch 384i instrument) publication in Molecular Pharmacology (2020)

    Authors:
    A. Hinckley C., Kuryshev Y., Sers A., Barre A., Buisson B., Naik H., Hajos M.

    2020 - Automated Patch Clamp in Drug Discovery: major breakthroughs and innovation in the last decade

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i instrument)   icon pl   Patchliner and   icon pap   Port-a-Patch publication in Expert Opinion on Drug Discovery (2020)

    Authors:
    Obergrussberger A., Friis S., Brüggemann A., Fertig N.

    2020 - Allosteric mechanism for KCNE1 modulation of KCNQ1 potassium channel activation

    icon sp96  Syncropatch 768 PE publication in eLife (2020)

    Authors:

    Kuenze G., Vanoye C.G., Desai R.R., Adusumili S., Brewer K.R., Woods H., McDonald E.F., Sanders C.R., George Jr. A.L.

    2020 - Accounting for variability in ion current recordings using a mathematical model of artefacts in voltage-clamp experiments

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) publication in Philosophical Transactions of the Royal Society A (2020)

    Authors:
    Lei, C.L., Clerx, M., Whittaker, D.G., Gavaghan, D.J., de Boer, T.P., Mirams, G.R.

    2020 - A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm

    icon pl   Patchliner and   icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i instrument) publication in Toxicology and Applied Pharmacology (2020)

    Authors:
    Ridder B.J., Leishman D.J., Bridgland-Taylor M., Samieegohar M., Han X, Wu W.W., Randolph A., Tran P., Sheng J., Danker T., Lindqvist A., Konrad D., Hebeisen S., Polonchuk L., Gissinger E., Renganathan M., Koci B., Wei H., Fan J., Levesque P., Kwagh J., Imredy J., Zhai J., Rogers M., Humphries E., Kirby R., Stoelzle-Feix S., Brinkwirth N., Rotordam M.G., Becker N., Friis S., Rapedius M., Goetze T.A., Strassmaier T., Okeyo G., Kramer J., Kuryshev Y., Wu C., Himmel H., Mirams G.R., Strauss D.G., Bardenet R., Li Z.

    2020 - A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model

     icon sp96   SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in the Journal of Pharmacological and Toxicological Methods (2020)

    Authors:

    Han X., Samieegohar M., Ridder B.J., Wu W.W., Randolph A., Tran P., Sheng J., Stoelzle-Feiz S., Brinkwirth N., Rotordam M.G., Becker N., Friis S., Rapedius M., Goteze T.A., Strassmaier T., Okeyo G., Kramer J., Kuryshev Y., Li Z.

    2019 - Synthesis by native chemical ligation and characterization of the scorpion toxin AmmTx3

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Bioorganic & Medicinal Chemistry (2019)

    Authors:
    Zoukimian C., Meudal H., De Waard S., Ait Quares K., Nicolas S., Canepari M., Béroud R., Landon C., De Waard M., Boturyn D.

    2019 - Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Journal of Medicinal Chemistry (2019)

    Authors:
    McKerrall S.J., Nguyen T., Lai K.W., Bergeron P., Deng L., DiPasquale A., Chang J.H., Chen J., Chernov-Rogan T., Hackos D.H., Maher J., Ortwine D.F., Pang J., Payandeh J., Proctor W.R., Shields S.D., Vogt J., Ji P., Liu W., Ballini E., Schumann L., Tarozzo G., Bankar G., Chowdhury S., Hasan A., Johnson J.P. Jr., Khakh K., Lin S., Cohen C.J., Dehnhardt C.M., Safina B.S., Sutherlin D.P.

    2019 - Structural Basis of Nav1.7 Inhibition by a Gating-Modifier Spider Toxin

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Cell (2019)

    Authors:
    Xu H., Li T., Rohou A., Arthur C.P., Tzakoniati F., Wong E., Estevez A., Kugel C., Franke Y., Chen J., Ciferri C., Hackos D.H., Koth C.M., Payandeh J.

    2019 - Spectrum of KV2.1 Dysfunction in KCNB1‐Associated Neurodevelopmental Disorders

    icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 384/768i) Publication Annals of Neurology (2019)

    Authors: 
    Kang, S.K., Vanoye, C.G., Misra, S.N., Echevarria, D.M., Calhoun, J.D., O’Connor, J.B., Fabre, K.L., McKnight, D., Demmer, L., Goldenberg, P., Grote, L.E., Thiffault, I., Saunders, C., Strauss, K.A., Torkamani, A., van der Smagt, J., van Gassen, K., Carson, R.P., Diaz, J., Leon, E., Jacher, J.E., Hannibal, M.C., Litwin, J., Friedman, N.R., Schreiber, A., Lynch, B., Poduri, A., Marsh, E.D., Goldberg, E.M., Millichap, J.J., George Jr., A.L., Kearney, J.A.

    2019 - Role of High‐Throughput Electrophysiology in Drug Discovery

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i),   icon pl   Patchliner and   icon pap   Port-a-Patch review article in Current Protocols in Pharmacology (2019)

    Authors:
    Liu C., Li T., Chen J.

    2019 - Rapid characterisation of hERG channel kinetics II: temperature dependence

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Biophysical Journal (2019)

    Authors:
    Lei C.L., Clerx M., Beattie K.A., Melgari D., Hancox J.C., Gavaghan D.J., Polonchuk L., Wang K., Mirams G.R.

    2019 - Rapid characterisation of hERG channel kinetics I: using an automated high-throughput system

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Biophysical Journal (2019)

    Authors:
    Lei C.L., Clerx M., Beattie K.A., Gavaghan D.J., Polonchuk L., Mirams G.R., Wang K.

    2019 - Pharmacological activation of IKr in models of long QT Type 2 risks overcorrection of repolarization

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Cardiovascular Research (2019)

    Authors:
    Perry M.D., Ng C-A., Mangala M.M., Ng T.Y.M., Hines A.D., Liang W., Xu M.J.O., Hill A.P., Vandenberg J.I.

    2019 - In vitro and in vivo characterization of a synthetic scorpion toxin AmmTx3, a potent inhibitor of cardiac voltage-gated potassium channel Kv4.2

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) publication in Archives of Cardiovascular Diseases Supplements (2019)

    Authors
    Nicolas S., Zoukimian C.,Meuda H., De Waard S., Ait Ouares K., Canepari M., Beroud R., Landon C., De Waard M., Boturyn D.

    2019 - High-throughput phenotyping of heteromeric human ether-à-go-go-related gene potassium channel variants can discriminate pathogenic from rare benign variants

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Heart Rhythm (2019)

    Authors:
    Ng C-A., Perry M.D., Liang W., Smith N.J., Foo B., Shrier A., Lukacs G.L., Hill A.P., Vandenberg J.I.

    2019 - High Throughput Characterization of KCNB1 Variants Associated with Developmental and Epileptic Encephalopathy

    icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 384/768i) Pre-publication in bioRxiv (2019)

    Authors: 
    Kang, S.K., Vanoye, C.G., Misra, S.N., Echevarria, D.M., Calhoun, J.D., O’Connor, J.B., Fabre, K.L., McKnight, D., Demmer, L., Goldenberg, P., Grote, L.E., Thiffault, I., Saunders, C., Strauss, K.A., Torkamani, A., van der Smagt, J., van Gassen, K., Carson, R.P., Diaz, J., Leon, E., Jacher, J.E., Hannibal, M.C., Litwin, J., Friedman, N.R., Schreiber, A., Lynch, B., Poduri, A., Marsh, E.D., Goldberg, E.M., Millichap, J.J., George Jr., A.L., Kearney, J.A.

    2019 - Functional consequences of a KCNT1 variant associated with status dystonicus and early‐onset infantile encephalopathy

    icon sp96   SyncroPatch 384PE (a predeccessor model of the SyncroPatch 384i) publication in Annals of Clinical and Translational Neurology (2019)

    Authors:
    Gertler T.S., Thompson C.H., Vanoye C.G., Millichap J.J., George Jr A.L.

    2019 - Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) article in European Journal of Pharmacology (2019)

    Authors:
    Asahi Y., Nomura F., Abe Y., Doi M., Sakakura T., Takasuna K., Yasuda K.

    2019 - Development of Photocrosslinking Probes Based on Huwentoxin-IV to Map the Site of Interaction on Nav1.7

    icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 384/768i) Publication in Cell Chemical Biology (2019)

    Authors: 
    Tzakoniati F., Xu H., Li T., Garcia N., Kugel C., Payandeh J., Koth C.M., Tate E.W.

    2019 - Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

    icon sp96   SyncroPatch 384PE article in Bioorganic and Medicinal Chemistry Letters (2019)

    Authors:
    Sharma, S.H., Pablo J.L., Montesinos, M.S., Greka, A., Hopkins, C.R.

    2019 - Compounds commonly used in equine medicine inhibits the voltage-gated potassium channel Kv11.1

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Research in Veterinary Science (2019)

    Authors:
    Calloe K., Rognant, S., Friis S., Shaughnessy C., Klaerke D.A., Trachsel D.

    2019 - Chemical Synthesis, Proper Folding, Nav Channel Selectivity Profile and Analgesic Properties of the Spider Peptide Phlotoxin 1

    icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) publication in Toxins (2019)

    Authors: 
    Nicolas S., Zoukimian C., Bosmans F., Montnach J., Diochot S., Cuypers E., De Waard S., Béroud R., Mebs D., Craik D., Boturyn D., Lazdunski M., Tytgat J., De Waard M.

    2019 - Aptamer Efficacies for In Vitro and In Vivo Modulation of αC-Conotoxin PrXA Pharmacology

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Molecules (2019)

    Authors:
    Taiwe G.S., Montnach J., Nicolas S., De Waard S., Fiore E., Peyrin E., El-Aziz T.M.A., Amar M., Molgó J., Ronjat M., Servent D., Ravelet C., De Waard M.

    2019 - A Novel Gain-Of-Function Mutation Of Piezo1 Is Functionally Affirmed In Red Blood Cells By High-Throughput Patch Clamp

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Haematologica (2019)

    Authors:
    Rotordam G.M., Fermo E., Becker N., Barcellini W., Brüggemann A., Fertig N., Egée S., Rapedius M., Bianchi P., Kaestner L.

    2018 - Towards Novel Bioactive Antiperspirants for Cosmetic Applications

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in IFSCC (2018)

    Authors:
    Ertongur-Fauth T., Fischer S., Hartmann D., Brüggemann A., Seeger V., Kleber A., Krohn M.

    2018 - NaV Channels: Assaying Biosynthesis, Trafficking, Function

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) article in The Surfaceome (2018)

    Authors:
    Tomaselli G.F., Farinelli F.

    2018 - Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Nav1.5 gain-of-function mutation (G213D)

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) -related publication in International Journal of Cardiology (2018)

    Authors:
    Calloe K., Broendberg A.K., Christensen A.H., Pedersen L.N., Olesen M.S., de los Angeles Tejada M., Friis S., Thomsen M.B., Bundgaard H., Jensen H.K.

    2018 - Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors

    icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 384/768i)  publication in PNAS

    Authors: 
    Chernov-Rogan T., Li T., Lu G., Verschoof H., Khakh K., Jones S.W., Beresini M.H., Liu C., Ortwine D.F., McKerrall S.J., Hackos D.H., Sutherlin D., Cohen C.J., and Chen J.

    2018 - High-Throughput Functional Evaluation of KCNQ1 Decrypts Variants of Unknown Significance

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) article in Circulation: Genomic and Precision Medicine (2018)

    Authors:
    Vanoye C.G., Desai R.R., Fabre K.L., Gallagher S.L., Potet F., DeKeyser J.M., Macaya D., Meiler J, Sanders C.R, and George Jr. A.L.

    2018 - Developing High-Throughput Assays to Analyze and Screen Electrophysiological Phenotypes

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) book chapter in Phenotypic Screening (2018)

    Authors:
    Pan J.Q., Baez-Nieto D., Allen A., Wang HR., Cottrell J.R.

    2018 - An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery

    icon sp96   SyncroPatch 384/768PE (a predecessor model of SyncroPatch 384/768i) and   icon pl   Patchliner publication in Expert Opinion on Drug Discovery

    Authors: 
    Obergrussberger A., Goetze T.A., Brinkwirth N., Becker N., Friis S., Rapedius M., Haarmann C., Rinke-Weiß I., Stölzle-Feix S., Brüggemann A., George M., Fertig N.

    2017 - Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions

    icon sp96  SyncroPatch 768PE (a predecessor model of SyncroPatch 384/768i) publication in Nature Communications (2017)

    Authors: 
    Chiang E.Y., Li T., Jeet S., Peng I., Zhang J., Lee W. P., DeVoss J., Caplazi P., Chen J., Warming S., Hackos D.H., Mukund S., Koth C.M., Grogan J.L.

    2017 - High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE

    icon sp96  SyncroPatch 768PE (a predecessor model of SyncroPatch 384/768i) publication in PLoS One (2017)

    Authors: 
    Li T, Lu G, Chiang E.Y., Chernov-Rogan T., Grogan J.L., Chen J.

    2017 - Characterization of a KCNB1 variant associated with autism, intellectual disability, and epilepsy

    icon sp96  SyncroPatch 768PE (a predecessor model of SyncroPatch 384/768i) publication in Neurology Genetics (2017)

    Authors: 
    Calhoun, J.D., Vanoye, C.G., Kok, F., George, A.L., Kearney, J.A.

    2017 - Automated Patch Clamp Recordings of Human Stem Cell- Derived Cardiomyocytes.

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) book chapter in Stem Cell-Derived Models in Toxicology (2017)

    Authors: 
    Obergrussberger A., Haarmann C., Stölzle-Feix S., Becker N., OhtsukiA., Brüggemann A., George M., Fertig N.

    2016 - Use-dependent Block of Human Cardiac Sodium Channels by GS967

    icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Molecular Pharmacology (2016)

    Authors: 
    Potet F., Vanoye C.G., George Jr. A.L.

    2016 - pH-sensitive K+ channel TREK-1 is a novel target in pancreatic cancer

    icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Biochimica et Biophysica Acta (2016)

    Authors: 
    Sauter D.R.P., Sørensen C.E., Rapedius M., Brüggemann A., Novak I.

    2016 - Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module

    icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Journal of Lab Automation (2016)

    Authors: 
    Obergrussberger A., Brüggemann A., Goetze T.A., Rapedius M., Haarmann C., Rinke I., Becker N., Oka T., Ohtsuki A., Stengel T., Vogel M., Steindl J., Mueller M., Stiehler J., George M., Fertig N.

    2015 - Novel screening techniques for ion channel targeting drugs

    icon pl  Patchliner,   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) and   Icon CE   CardioExcyte 96 publication in Channels (2015)

    Authors: 
    Obergrussberger A., Stölzle-Feix S., Becker N., Brüggemann A., Fertig N., Möller C.

    2015 - Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp

    icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in BCM Pharmacology and Toxicology (2015) 

    Authors: 
    Haraguchi Y., Ohtsuki A., Oka T., Shimizu T.

    2014 - New strategies in ion channel screening for drug discovery: are there ways to improve its productivity?

    icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Journal of Laboratory Automation (2014)

    Authors: 
    Farre C., Fertig N.

    2014 - Early identification of hERG liability in drug discovery programs by automated patch clamp

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Frontiers in Pharmacology (2014)

    Authors: 
    Danker T., Moeller C.

    2012 - Natural and artificial ion channels for biosensing platforms

    icon pap   Port-a-Patch,   icon pl   Patchliner,   icon sp96   SyncroPatch 96 ((a predecessor model of SyncroPatch 384PE) and   icon vpp   Vesicle Prep Pro publication in Analytical and Bioanalytical Chemistry (2012)

    Authors: 
    Steller L., Kreir M., Salzer R.

    2012 - HTS techniques for patch clamp-based ion channel screening - economy and advances

    icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Expert Opinion on Drug Discovery (2012)

    Authors: 
    Farre C. and Fertig N.

    2011 - State-of-the-art automated patch clamp devices: heat activation, action potentials, and high throughput in ion channel screening

    icon pap   Port-a-Patch,   icon pl  Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Frontiers in Pharmacology (2011)

    Authors: 
    Stoelzle S., Obergrussberger A., Brüggemann A., Haarmann C., George M., Kettenhofen R., Fertig N.

    2011 - Automated electrophysiology makes the pace for cardiac ion channel safety screening

    icon pl  Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Frontiers in Pharmacology (2011)

    Authors: 
    Möller C., Witchel H.

    2010 - Renaissance of ion channel research and drug discovery by patch clamp automation

    icon pap  Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE)  publication in Future Medical Chemistry (2010)

    Authors:
    Farre C. and Fertig N.

    2009 - DtpB (YhiP) and DtpA (TppB, YdgR) are prototypical proton-dependent peptide transporters of Escherichia coli

    Icon N1  SURFE²R ONE (a predecessor model of SURFE²R N1) publication in The FEBS Journal (2009)

    Authors:
    Harder D., Stolz J., Casagrande F., Obrdlik P., Weitz D., Fotiadis D., Daniel H.

    Product Sheets

    SyncroPatch 384 - Product Sheet

    icon sp96   SyncroPatch 384 product sheet:   logo pdf   (3.6 MB)

    SyncroPatch 384/768PE - 产品单页

    icon sp96   SyncroPatch 384/768PE 产品单页:   logo pdf   (7.6 MB)

    SyncroPatch 384PE Product Flyer - PatchControl 384/DataControl 384 Version 1.6 Software update Jan. 2019

    icon pl   SyncroPatch 384 (a predecessor model of SyncroPatch 384i)

    software update flyer: PatchControl 384/DataControl 384 Version 1.6   logo pdf   (1 MB)

    Posters

    2021 - Reliable identification of cardiac liability in drug discovery using automated patch clamp: Considerations and best practices for high throughput recordings of NaV 1.5

    icon pl   Patchliner and   icon sp96  SyncroPatch 384i (a predecessor model of SyncroPatch 384) Physiology 2021  logo pdf   (2 MB)

    2021 - Development and validation of ASIC1a ligand-gated ion channel drug discovery assays on automated patch clamp platforms

    icon pl   Patchliner and   icon sp96  SyncroPatch 384i (a predecessor model of SyncroPatch 384) Biophysical Society Meeting 2021  logo pdf   (2 MB)

    2021 - Activation and inhibition of assay-ready TRPA1 and TRPV cells: an automated patch clamp study

    icon pap Port-a-Patch, icon pl   Patchliner and   icon sp96  SyncroPatch 384i (a predecessor model of SyncroPatch 384) Biophysical Society Meeting 2021  logo pdf   (1.5MB)

    2020 - Reliable Identification of hERG Liability in Drug Discovery by Automated Patch Clamp

     icon sp96   SyncroPatch 384i (a predecessor model of SyncroPatch 384) and   icon pl   Patchliner poster, 64th Annual Meeting of the Biophysical Society   logo pdf   (1.3 MB)

    2020 - Kinetic and pharmacological properties of P2X3 and P2X2/3 receptors

     icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384 instrument) and   icon pl   Patchliner poster, 64th Annual Meeting of the Biophysical Society   logo pdf   (1.8 MB)

    2020 - Unattended Screening Workflow in a 384-well Automated Patch Clamp System

     icon sp96   SyncroPatch 384i  (a predecessor model of SyncroPatch 384) poster, SPS 2020   logo pdf   (1.3 MB)

    2018 - Expression and pharmacology of GluA2-containing AMPA receptors in cell lines and stem cell-derived neurons

    icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 384PE  (a predecessor model of the SyncroPatch 384) poster, Europhysiology Meeting 2018  logo pdf   (0.9 MB)

    2018 - Combining electrophysiology and contractility recordings for more complete assessment of hiPSC-CMs

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i),   icon pl   Patchliner and   Icon CardioExcyte 96 simpel RGB   CardioExcyte 96 poster, Europhysiology Meeting 2018  logo pdf   (1.4 MB)

    2017 - lnvestigation of the Ion Channels hTMEM16A/Ano1 and TRPC5 and their Modulation by Intracellular Calcium

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) poster, BPS Meeting 2017  logo pdf   (1.3 MB)

    2017 - Activation of CFTR channels in absence of internal fluoride using a highly parallel automated patch clamp system

    icon sp96   SyncroPatch 384PE poster (a predecessor model of the SyncroPatch 384), BPS Meeting 2017  logo pdf   (1.5 MB)

    2018 - Investigating pain pathways by inhibition of voltage-gated sodium channels

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and   icon pl   Patchliner poster, FENS Meeting 2018  logo pdf   (2.5 MB)

    2017 - Pharmacological Characterization of the NMDA A-B-C by Automated Patch Clamp

    icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) poster, BPS Meeting 2017  logo pdf   (4.9 MB)

    2018 - High throughput automatic patch clamp: Applications for Safety Pharmacology

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) poster, JSPS Meeting 2018  logo pdf   (2.3 MB)

    2018 - Optogenetic technologies enable high throughput ion channel drug discovery and toxicity screening

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and   Icon CE   CardioExcyte 96 poster, Biophysics Annual Meeting 2018  logo pdf   (1.3 MB)

    2017 - Cardiomyocytes in Voltage Clamp and Current Clamp by Automated Patch Clamp

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and   icon pl   Patchliner poster, BPS Meeting 2017  logo pdf   (1.7 MB)

    2016 - Next level toxicity screening: From single channel to overall cell behavior

    Icon Orbit Mini   Orbit mini,   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) poster, Meeting of the French Society of Toxinology (SFET) 2015  logo pdf   (0.9 MB)

    2015 - Organellar Transporters and Ion Channels - How to access their electrophysiology by using the SURFE2R technology and Planar Patch Clamp

    Icon N1   SURFE²R N1 and   icon sp96   SyncroPatch 96 (a predecessor model of the SyncroPatch 384) and   icon pap   Port-a-Patch poster, GRC - Organellar Channels and Transporters 2015   logo pdf   (1.6 MB)

    2015 - The backstage pass to study your favorite TRP channel

    icon pap   Port-a-Patch and   icon pl   Patchliner and   icon sp96   SyncroPatch 384PE  (a predecessor model of the SyncroPatch 384) poster, TRP Meeting 2015   logo pdf   (2.2 MB)

    2015 - High Throughput Automated Patch Clamp of Ion Channels Important in Cardiac Safety and Drug Discovery

    icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384) poster, Chantest Meeting 2015   logo pdf   (1.9 MB)

    2015 - Complementary automated patch clamp, extracellular field potential and impedance recordings of iPSCs: safety screening tool box for the future

    icon pl   Patchliner and   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384) poster,   SPS 2015   logo pdf   (2.7 MB)

    Presentations

    2020 - High Throughput screening of missense variants in KCNH2

    icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) presentation (slide deck)  logo pdf (3 MB)

    2018 - Innovations for cell monitoring in safety and toxicity assays

    Icon CE   CardioExcyte 96 &   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) presentation (slide deck)   logo pdf   (3.2 MB)



     

     

     

     

    We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.